Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
MRHC showed comparable bioavailability to IRHC based on cortisol AUC after 20 mg administration.
The IFA score is potentially clinically useful because of its high validity and reliability.
An FGFR/FGF-based gene signature identified in our study appears to predict long-term benefit from bevacizumab.
The safety profile was generally consistent with previous studies of RZB in psoriasis.
UP and inflammation were reduced in patients with active RA in Japan in both SAR single-drug treatment and SAR + csDMARDs treatment groups.
Among patients achieving complete response, the estimated 1-year rate of continued response was 68% (95% CI, 45-83).
The use of combined intraocular and sub-Tenons capsule TA is not recommended as an add-on booster to vitrectomy surgery following OGT.
Daridorexant reduced the number and duration of longer wake bouts throughout the night compared with placebo, corresponding with improved daytime functioning.
Conclusion: PSMA-targeted PET/MRI-guided biopsy is a reliable, less invasive method for detecting and characterizing PCa in a cohort with moderately increased PSA values, potentially reducing unnecessary biopsies and provides...
Fenofibrate may represent a promising add-on therapy in patients with mild-to-moderate UC by modulating inflammation and improving QoL.
Protocols R or IR proved to be inferior to the R + IR laser photobiomodulation protocol.
Our findings suggest that, in patients with rate-controlled AF, digoxin positively modulates LAS when compared with bisoprolol.
In this phase 3 trial, the overall incidence of grade ≥ 2 rectal toxicity was low and was not significantly different between the 2 arms.
Faricimab up to Q16W offered durable vision gains and anatomic improvements up to 2 years in patients with DME in the YOSEMITE Japan subgroup.
Prompt diagnosis of AS and early treatment with IV golimumab may yield more robust improvements in disease activity.
EDRT results in improved LC with good functional outcomes without a significant increase in toxic effects.
IP chemotherapy enhances the survival rates of patients with EOC with an immune-Hot phenotype in the tumor microenvironment prior to treatment.
The study confirms SDRT as a superior ablative treatment, indicating that effective ablation of oligometastatic lesions is associated with significant mitigation of distant metastatic progression.
Among participants with emergence of nonsusceptibility to meropenem, clinical outcomes were similar to overall clinical outcomes in the ASPECT-NP meropenem arm.
CoQ10 significantly improved disease severity, QoL, and inflammatory and oxidative stress markers in JIA patients with an excellent safety profile.
Rezafungin demonstrated similar real-world benefits and safety to caspofungin in the ReSTORE China cohort.
On ARST1431, tumors >5 cm at diagnosis had poor local control despite dose escalation to 59.4 Gy.
NT-501 for MacTel resulted in statistically significantly reduced EZA loss compared with sham procedures.
There was a slight increase in patients achieving sustained full symptom relief at Week 52 and a decrease in absolute neutrophil count with increasing sarilumab C trough plateauing at 20-25 mg/L.
Several clinical scenarios were identified where dichotomous immune responses were estimated with >95% confidence based on combinations of predictive variables.
Tezepelumab reduced exacerbations compared with placebo, and was well tolerated, in NAVIGATOR patients with severe, uncontrolled asthma recruited in Japan.
BNO 1045 is, in addition to reducing symptoms, comparable to fosfomycin treatment in reducing the local inflammatory response associated with uUTI.
In older women after hip fracture, fewer depressive symptoms and better mental health were associated with higher psychological resilience.
Although well tolerated, eculizumab treatment did not show significant effects on motor function recovery compared to placebo in patients with GBS.
URLi can control breakfast PPG better than insulin lispro in adults with T2D in China, while it is non-inferior in improving HbA1c.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
